Academic Journal
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK
| العنوان: | External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK |
|---|---|
| المؤلفون: | Aruni Ghose, Alessio Signori, Nicholas Brown, Sophia Haywood, Jose Tapia, Anupama Vijay, Michael Cheung, Ishika Mahajan, Ondrej Fiala, Ritika Abrol, Vishwani Chauhan, Yamin Shwe Yee Soe, Anum Zargham, Sophie Ashley, Michelle Smith, Orla Hardy, Emma Johnston, Abdullah Sarwer, Kyaw Kyaw Tun, Amarnath Challapalli, Roshani Shrestha, Yüksel Ürün, James Meegan, Pasquale Rescigno, Joanne Parkes, Benjamin Smalley, Shobana Anpalakhan, Francesco Buono, Alexandr Poprach, Jeremy Yuen Chun Teoh, Veronica Murianni, Fabio Catalano, Davide Bimbatti, Sebastiano Buti, Giuseppe Fornarini, Giuseppe Banna, Sara Elena Rebuzzi |
| المساهمون: | Ghose, Aruni, Signori, Alessio, Brown, Nichola, Haywood, Sophia, Tapia, Jose, Vijay, Anupama, Cheung, Michael, Mahajan, Ishika, Fiala, Ondrej, Abrol, Ritika, Chauhan, Vishwani, Shwe Yee Soe, Yamin, Zargham, Anum, Ashley, Sophie, Smith, Michelle, Hardy, Orla, Johnston, Emma, Sarwer, Abdullah, Kyaw Tun, Kyaw, Challapalli, Amarnath, Shrestha, Roshani, Ürün, Yüksel, Meegan, Jame, Rescigno, Pasquale, Parkes, Joanne, Smalley, Benjamin, Anpalakhan, Shobana, Buono, Francesco, Poprach, Alexandr, Yuen Chun Teoh, Jeremy, Murianni, Veronica, Catalano, Fabio, Bimbatti, Davide, Buti, Sebastiano, Fornarini, Giuseppe, Banna, Giuseppe, Elena Rebuzzi, Sara |
| بيانات النشر: | SAGE PUBLICATIONS LTD |
| سنة النشر: | 2024 |
| المجموعة: | Università di Parma: CINECA IRIS |
| مصطلحات موضوعية: | Settore MEDS-09/A - Oncologia medica |
| الوصف: | Objective: First-line immune-combination therapy based on immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) are the new mainstay in metastatic renal cell cancer (mRCC). In this setting, there is a dearth of standard prognostic/predictive parameters to guide treatment choice. The novel prognostic Meet-URO score (IMDC score + bone metastases and neutrophil-to-lymphocyte ratio - NLR) showed a higher prognostic accuracy than IMDC in 306 patients on first-line nivolumab + ipilimumab in the Italian Expanded Access Program (PMID: 36493602). Hence, the necessity to externally validate and expand to other first-line immune-combination settings. Methods: Twenty-seven European centres were included. Baseline patient and tumour characteristics were collected, including the IMDC score along with the presence of pre-treatment bone metastases, neutrophils, and lymphocytes for calculating the Meet-URO score. The prognostic performance of Meet-URO and IMDC scores were compared and defined by the Harrell’s c-index. Results: 1174 mRCC patient data was retrospectively collected. The median age was 64. 72.8% were male, 54.2% received nephrectomy, 62% were metastatic at diagnosis and 86.7% had clear-cell histology. 35% had bone metastases and 51.6% had NLR ⩾ 3.2. 672 (57.2%) patients received ICI-ICI (nivolumab + ipilimumab) whereas 502 (42.8%) an ICI-TKI combination, mainly avelumab + axitinib (27.1%) and pembrolizumab + lenvatinib (14.3%). Overall, median overall survival (mOS) was 36.2 months (95% CI 31.1 – 38.5) with a median follow up of 15.5 months. The c-index of Meet-URO resulted higher than IMDC score (0.68 vs 0.65). In particular, the mOS resulted more distinctive within the Meet-URO prognostic groups: 45.8 months for group 1 (12.9% of patients), 55.0 for group 2 (25.7%), 38.1 for group 3 (23.5%), 20.9 months for group 4 (29.6%) and 10.4 for group 5 (8.2%). On the other hand, mOS was 45.8 months for IMDC favorable-risk (19.5% of patients), 38.2 for intermediate-risk (53.7%) and 16.2 for poor-risk ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/wos/WOS:001316025900001; volume:16; firstpage:13; lastpage:14; numberofpages:2; journal:THERAPEUTIC ADVANCES IN UROLOGY; https://hdl.handle.net/11381/3006147 |
| DOI: | 10.1177/17562872241277067 |
| الاتاحة: | https://hdl.handle.net/11381/3006147 https://doi.org/10.1177/17562872241277067 |
| رقم الانضمام: | edsbas.E1B92BA8 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1177/17562872241277067 |
|---|